Drug intelligence / Profile preview

NVX103

Development stage: Preclinical
Lead developer: NeoVascularX
Administration: Topical, Ophthalmic

Overview

NVX103 (also known as AMD101 Topical DR Product) is a preclinical-stage topical ophthalmic drug candidate being developed by NeoVascularX for the treatment of diabetic retinopathy (DR). It is designed as a next-generation topical formulation intended to deliver therapeutic agents to the posterior segment of the eye, specifically targeting the sub-retinal tissue. While the specific molecular mechanism of action and biological target have not been publicly disclosed, the product aims to provide a non-invasive alternative to intravitreal injections for patients with diabetic retinopathy. NVX103 is part of a pipeline of products utilizing a proprietary delivery technology intended to enhance efficacy and patient convenience in treating retinal vascular diseases.

Other names: AMD101AMD-101AMD 101

Beyond the preview

Go deeper on NVX103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NVX103.

Explore the full profile